The Technical AnalystExchange: OTC Sector: Healthcare Industry: Biotechnology
Starpharma Holdings Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.750
America/New_York / 2 mai 2024 @ 14:12
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 30.90 mill |
| EPS: | -0.140 |
| P/E: | -5.36 |
| Earnings Date: | Feb 28, 2024 |
| SharesOutstanding: | 41.20 mill |
| Avg Daily Volume: | 0.0020 mill |
| RATING 2024-05-02 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.36 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -5.36 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.175 (-123.40%) $-0.925 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.713 - 0.787 ( +/- 4.93%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.750 (0.00% ) |
| Volume | 0.0010 mill |
| Avg. Vol. | 0.0020 mill |
| % of Avg. Vol | 51.28 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SPHRY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SPHRY
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Latest Press Releases
Latest News
